PAREA

Germany becomes the first EU country to approve compassionate use of psychedelic therapy. Patients who haven’t responded to conventional depression treatments can now access it at CIMH and the OVID Clinic. A major step toward broader access to psychedelic care in Europe! tinyurl.com/compassionat...

We’re happy to welcome Irish Doctors for Psychedelic Assisted Therapy as the newest member of PAREA’s Community Supporters network. This fall, PAREA will join the Psychedelic Research Conference, co-hosted by IDPAT and Trinity College Dublin. More here: tinyurl.com/idpat

Europe Invests in the Future of Psychedelic Science: INTEGRATE Doctoral Network Launches with €4.3 Million in Funding — PAREA A second major EU-funded project in psychedelic science, following PsyPal, will start in the coming months. INTEGRATE will be a doctoral training network supported by €4.3 million in EU funding throug...

Big news for psychedelic research in Europe:

The new €4.3M INTEGRATE project will train 16 PhDs across Europe. Funded by Marie Skłodowska-Curie Actions, it marks a major step forward. PAREA is proud to support by hosting secondments.

More here: parea.eu/parea-news/i...

New expert commentary outlines five priorities to advance psychedelic therapies in mental health care — PAREA A new expert commentary is outlining five priorities to advance psychedelic therapies in mental health care. Published on The Mental Elf—an online resource on mental health research— the piece follow...

A new expert commentary published on The Mental Elf outlines five priorities to advance psychedelic mental health care. Co-authored by leading voices across sectors, it reflects growing momentum. PAREA is pleased to have contributed input. Learn out more about it here: parea.eu/parea-news/i...

Big news: PAREA just received a €50K grant from Entheon Foundation to strengthen EU advocacy, push for more funding, and build capacity for psychedelic-assisted mental health treatments across Europe. Thanks to Entheon for backing this work!
Read more here: parea.eu/parea-news/e...

PAREA is delighted to welcome Nico Gusac to our team as our new Communications Officer!
With a multidisciplinary background and a deep commitment to mental health, culture, and ethics, Nico is passionate about healing as a relational and systemic process, convinced that community is medicine.

Today, the EU4Health Civil Society Alliance launched Health4Europe: a blueprint for the next EU Health Programme. As a proud member, PAREA endorses this call to keep health a top EU priority in the next MFF. Read the full proposal here: tinyurl.com/eu4healthblueprint

On February 26, 2025, during the Psychedelics as Medicine conference in Reykjavik, Iceland, representatives from all Nordic psychedelic associations signed the Manifesto for the Nordic Psychedelic Network Initiative. Learn more in our latest guest article by Cecilie Byholt Endresen: bit.ly/3TOXmyg

We’re proud to be representing the PsyPal project @psypaleu.bsky.social at Psychedelic Science, in Denver, and at the European Academy of Neurology Congress, in Helsinki!

Compass Pathways released topline data from the first-ever Phase 3 trial of a classical psychedelic - COMP360 psilocybin - for treatment-resistant depression: significant improvements and no new safety concerns. Attention now turns to the larger COMP006 trial.

PAREA is turning 3! 🎉

We’ve spent the past days in Denver at Psychedelic Science 2025 and now at the European Academy of Neurology @ean.org Congress in Helsinki connecting with peers and team members face-to-face.

Thanks to everyone who’s supported our journey — we’re just getting started.

🧠 One week until #EAN2025 in Helsinki!
We'll be there 21–24 June with a booth in the Neurohood + a session at the Scientific Theatre.

Come learn about the evolving frontier of psychedelic innovation in neurology, and about EU trial PsyPal (@psypaleu.bsky.social)! tinyurl.com/ean-session

PAREA will be at Psychedelic Science 25 next week, in Denver, Colorado!
🗓️Thursday, 4:30 PM “Progress in the EU: Lessons from Multi-Stakeholder Processes”
🗓️Friday, 2:45 PM “The Potential for PAT in Conflict-Affected Populations: Ukraine and the Balkanss”
For 15% off, use SPEAKER15: lnkd.in/dCQiuar9

PAREA submitted our consultation response on the EU Biotech Act, outlining recommendations to unlock mental health innovation:
• Support for early-stage biotechs
• Dedicated EU Mental Health Innovation Fund
• Pan-European trial infrastructure
🔗Full submission: ec.europa.eu/info/law/bet...

The EUDA released its European Drug Report, highlighting growing interest in psychedelics for therapeutic use. Research on psilocybin, MDMA, DMT, and LSD for PTSD and depression is advancing. New funding includes €6.5M for psychedelic therapy in palliative care. www.euda.europa.eu/publications...

🚨 Czech Parliament passes law allowing psilocybin therapy for depression, anxiety, and addiction in licensed clinical settings. This positions Czechia as a leader in responsible psychedelic use. PAREA applauds this evidence-based approach. Read more here: parea.myflodesk.com/ysbmi7ib6b

The WHO has issued a rapid communication on its forthcoming guideline on controlled medicines, on which PAREA participated as an external reviewer. tinyurl.com/who-gl-rc

Today, we mourn the loss of Amanda Feilding, a defining force in the field of psychedelics.

As David Nutt shared: “She was an inspiring person and psychedelic visionary... our field would not have advanced as much as it has without her. And on top of all this, a great friend and colleague.”

This European Mental Health Week, we are proud to launch our new policy paper, urging the EU to lead in mental health innovation!

www.parea.eu/s/leading-no...

🚨 New EU Insights is out!
Catch up on PAREA & policy updates from across Europe, including:
- MAPS training in Ukraine
- ⏳ Final day to join GPS2025 bit.ly/GPS2025-survey
- New Horizon EU funding opportunities for psychedelics
📬 Read the full newsletter: tinyurl.com/insights-may25

You can still contribute to the largest data-gathering effort on real-world psychedelic use by participating in #GPS2025: bit.ly/GPS2025-survey

Available in 18 languages, takes 20–30 minutes to complete, and entirely anonymous. The deadline is next week, May 16.

On May 12, the Champalimaud Foundation @champalimaudf.bsky.social will host the public presentation of multidisciplinary recommendations for the clinical use of psychedelics in Portugal. Check out the event here: tinyurl.com/cf-12may

Updated link: bit.ly/GPS2025-survey

🚀 We’re excited to announce the launch of the GPS 2025 – the world’s largest study of real-world psychedelic use!
The survey is open May 1–16 for adults 21+, in 18 languages.
Take part here: www.gps2025.com/survey

#GPS2025

The third edition of Finland’s interdisciplinary psychedelic conference is on the horizon! Psykedeelit 2025: Challenging Psychedelics will take place October 2–4 in Turku.

The call for abstracts is closing soon —read more and submit your proposals here: psyty.fi/psykedeelit2...

🧠 PAREA is joining the 2025 European Academy of Neurology Congress in Helsinki, 21-23 June!
Connect with us at out booth in the Neurohood - we’re eager to share our work at the intersection of brain health and psychedelic innovation with the neurology community!
Register here: tinyurl.com/ean-reg

PAREA’s involvement continued as our Project Officer spoke about PsyPal as a key research initiative shaping the future of psychedelic therapies in Europe @breakingconvention.bsky.social

Earlier this month, PAREA contributed to a @psypaleu.bsky.social workshop organised by @iese.bsky.social in Barcelona. The event gathered stakeholders to explore how psychedelics can be integrated into palliative care, within and beyond the PsyPal project.

PAREA has provided feedback on the European Commission’s initiative for a new multidisciplinary life sciences strategy, proposing four key actions to position Europe as a global leader in mental health innovation. Read more: tinyurl.com/lss-web-post

We stand with our fellow co-signatories in calling on the European Commission for the urgent adoption of the 2025 EU4Health Work Plan and full-year operational funding for health civil society organisations (CSOs). tinyurl.com/eu4health-ec